Please use this identifier to cite or link to this item: https://doi.org/10.1023/B:MCBI.0000041859.60354.f5
DC FieldValue
dc.titleHuman VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart
dc.contributor.authorLaw, P.K.
dc.contributor.authorHaider, Kh.
dc.contributor.authorFang, G.
dc.contributor.authorJiang, S.
dc.contributor.authorChua, F.
dc.contributor.authorLim, Y.T.
dc.contributor.authorSim, E.
dc.date.accessioned2014-12-01T06:55:16Z
dc.date.available2014-12-01T06:55:16Z
dc.date.issued2004-08
dc.identifier.citationLaw, P.K., Haider, Kh., Fang, G., Jiang, S., Chua, F., Lim, Y.T., Sim, E. (2004-08). Human VEGF165-myoblasts produce concomitant angiogenesis/myogenesis in the regenerative heart. Molecular and Cellular Biochemistry 263 (1) : 173-178. ScholarBank@NUS Repository. https://doi.org/10.1023/B:MCBI.0000041859.60354.f5
dc.identifier.issn03008177
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/113507
dc.description.abstractBioengineering the regenerative heart may provide a novel treatment for heart failure. On May 14, 2002, a 55-year-old man suffering from ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. As on August 28, 2002, his EKG was normal and showed no arrhythmia. His ejection fraction increased by 13%. He no longer experienced shortness of breath and angina as he did before the treatment. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine as immunosuppressant. Some myoblasts developed to become cardiomyocytes. Others transferred their nuclei into host cardiomyocytes through natural cell fusion. As yet others formed skeletal myofibers with satellite cells. De novo production of contractile filaments augmented the heart contractility. Human myoblasts transduced with VEGF165 gene produced six times more capillaries in porcine myocardium than in placebo. Xenograft rejection was not observed for up to 20 weeks despite cyclosporine discontinuation at 6 weeks. Pros and cons of autografts vs. allografts are compared to guide future development of heart cell therapy. © 2004 Kluwer Academic Publishers.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1023/B:MCBI.0000041859.60354.f5
dc.sourceScopus
dc.subjectMyoblast treatment
dc.subjectProof of concept
dc.typeArticle
dc.contributor.departmentNATIONAL UNIVERSITY MEDICAL INSTITUTES
dc.description.doi10.1023/B:MCBI.0000041859.60354.f5
dc.description.sourcetitleMolecular and Cellular Biochemistry
dc.description.volume263
dc.description.issue1
dc.description.page173-178
dc.description.codenMCBIB
dc.identifier.isiut000223918200018
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

7
checked on Jul 19, 2019

WEB OF SCIENCETM
Citations

6
checked on Jul 19, 2019

Page view(s)

94
checked on Jul 19, 2019

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.